ArticleScientific reports2016
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 39 citations in OpenAlex.
- Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.Scientific reports · 2026Article
- PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma.Cancer research communications · 2025Article
- Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB.Journal of translational medicine · 2025Article
- The acidic intrinsically disordered region of the inflammatory mediator HMGB1 mediates fuzzy interactions with CXCL12.Nature communications · 2024Article
- Innovative Experimental Ultrasound and US-Related Techniques Using the Murine Model in Pancreatic Ductal Adenocarcinoma: A Systematic Review.Journal of clinical medicine · 2023Review
- Dual-Layer Spectral CT as Innovative Imaging Guidance in Lung Biopsies: Could Color-Coded Z-Effective Images Allow More Diagnostic Samplings and Biomarkers Information?Journal of clinical medicine · 2023Article
- Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.Nature communications · 2023Article
- HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.Cancer research communications · 2023Article
- The DNA damage response pathway regulates the expression of the immune checkpoint CD47.Communications biology · 2023Article
- Article
- Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.Frontiers in immunology · 2023Article
- Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study.European radiology experimental · 2022Article
- Imaging in experimental models of diabetes.Acta diabetologica · 2022Review
- Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics.Frontiers in immunology · 2022Article
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Frontiers in oncology · 2022Review
- BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Review
- Immunogenic cell death and immunogenic surrender: related but distinct mechanisms of immune surveillance.Cell death & disease · 2021Article
- Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.Precision cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant Mesothelioma is a highly aggressive cancer, which is difficult to diagnose and treat. Here we describe the molecular, cellular and morphological characterization of a syngeneic system consisting of murine AB1, AB12 and AB22 mesothelioma cells injected in immunocompetent BALB/c mice, which allows the study of the interplay of tumor cells with the immune system. Murine mesothelioma cells, like human ones, respond to exogenous High Mobility Group Box 1 protein, a Damage-Associated Molecular Pattern that acts as a chemoattractant for leukocytes and as a proinflammatory mediator. The tumors derived from AB cells are morphologically and histologically similar to human MM tumors, and respond to treatments used for MM patients. Our system largely recapitulates human mesothelioma, and we advocate its use for the study of MM development and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.